Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
14 p, 4.6 MB Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases / De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ; Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ; Piscuoglio, Salvatore (University Hospital Basel (Basilea, Suïssa)) ; Gonzalez-Cao, Maria (Grup Quirónsalud (Barcelona, Catalunya)) ; Lim, Raymond S. (Memorial Sloan Kettering Cancer Center) ; De Filippo, Maria R. (Memorial Sloan Kettering Cancer Center) ; Fusco, Nicola (Memorial Sloan Kettering Cancer Center) ; Schultheis, Anne M. (Memorial Sloan Kettering Cancer Center) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Macedo, Gabriel S. (Memorial Sloan Kettering Cancer Center) ; Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ; Gómez, Patricia (Vall d'Hebron Institut d'Oncologia) ; Teixidó, Cristina (Grup Quirónsalud (Barcelona, Catalunya)) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Tresserra Casas, Francesc (Grup Quirónsalud (Barcelona, Catalunya)) ; Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ; Cortés, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ; Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630  
2.
9 p, 2.1 MB ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability / Scheffler, Matthias (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Schultheis, Anne M. (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Teixidó, Cristina (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Michels, Sebastian (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Morales Espinosa, Daniela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Hartmann, Wolfgang (University Hospital of Münster (Alemanya)) ; Merkelbach Bruse, Sabine (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Fischer, Rieke (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Schildhaus, Hans Ulrich (University Medical Center of Göttingen (Alemanya)) ; Fassunke, Jana (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Sebastian, Martin (University Hospital of Frankfurt (Alemanya)) ; Serke, Monika (Lung Clinic Hemer (Alemanya)) ; Kaminsky, Britta (Bethanien Hospital (Solingen, Alemanya)) ; Randerath, Winfried (Bethanien Hospital (Solingen, Alemanya)) ; Gerigk, Ulrich (Malteser Hospital Seliger Gerhard Bonn/Rhein-Sieg (Alemanya)) ; Ko, Yon-Dschun (Johanniter Hospital (Bonn, Alemanya)) ; Krüger, Stefan (Florence-Nightingale Hospital (Düsseldorf, Alemanya)) ; Schnell, Roland ; Rothe, Achim ; Kropf Sanchen, Cornelia (University Hospital of Ulm (Alemanya)) ; Heukamp, Lukas (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Rosell, Rafael (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Büttner, Reinhard (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Wolf, Jürgen (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. [...]
2015 - 10.18632/oncotarget.3387
Oncotarget, Vol. 6 Núm. 12 (april 2015)  

Vea también: autores con nombres similares
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.